Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP)

Luchsinger, J. A., Devanand, D., Goldberg, T. E., Cammack, S., Hernández-Santiago, G., Oishi, K., Jagust, W., Baker, S., Landau, S., Yenokyan, G., Betz, J., Mayers, S., Eyzaguirre, L. M., & Hanley, D. (2025). Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment. Alzheimer Disease & Associated Disorders, 39(2), 123–133. https://doi.org/10.1097/wad.0000000000000677
Authors:
José A Luchsinger
Davangere Devanand
Terry E Goldberg
Sam Cammack
Gabriela Hernández-Santiago
Kenichi Oishi
William Jagust
Suzanne Baker
Susan Landau
Gayane Yenokyan
Joshua Betz
Stephanie Mayers
Lindsay M Eyzaguirre
Daniel Hanley
Affiliated Authors:
José A Luchsinger
Davangere Devanand
Terry E Goldberg
Sam Cammack
Gabriela Hernández-Santiago
Columbia Affiliation:
Subjects:
Metformin (MeSH)
Cognitive Dysfunction (MeSH)
Alzheimer Disease (MeSH)
Hypoglycemic Agents (MeSH)
Author Keywords:
metformin
mild cognitive impairment
clinical trial
elink
Publication Type:
Article
Unique ID:
10.1097/wad.0000000000000677
PMID:
40434891
DOI:
10.1097/wad.0000000000000677
Journal:
Alzheimer Disease and Associated Disorders
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: